# Deargen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deargen

- Industry: Pharmaceuticals
- Headquarters: Daejeon, South Korea
- Website: www.deargen.me
- Total disclosed funding: $22M
- Latest round: Series B (Feb 24, 2022)
- Investors on record: 7

## About

Based in Daejeon, South Korea, and founded in 2016, Deargen Inc. is an AI-powered drug design biotech company that discovers new disease targets through artificial intelligence technology and applies it to develop treatment strategies for precision medicine by designing small molecules for new drugs. In February 2022, Deargen Inc. raised KRW 20 billion in a Series B funding from Hana Ventures, T.S. Investment., Korea Development Bank, Nvestor, and The Wells Investment. As of February 2022, Kilsoo Kang is the CEO of Deargen Inc.

Deargen’s product line includes drugs for the treatment of cardiovascular and metabolic diseases, neurological diseases, immune diseases, as well as anticancer drugs. The company is also running a 4D program, which is a new drug development pipeline from the discovery of hit substances. The 4D program includes DG-ONCO-T1, DG-ONCO-T2, DG-ONCO-T3, DG-ONCO-T4, DG-HF-T1, DG-HL-T1, and DG-ALS-T1. 
In addition, the company is also developing new drugs, such as NASH - target1, NASH - target2, NASH - target3, IPF - target1, IPF - target2, IPF - target3, IPF - target4, oncology, immunology, Hearing Loss, Alzheimer’s - target1, Alzheimer’s - target2, Alzheimer’s - target3, Alzheimer’s - target4, Alzheimer’s - target4, and more drugs through co-developed program. The company operates Dr.UG, an AI platform for new drug development based on its deep learning technology specializing in genome data analysis, biomarker prediction, molecule selection, and optimization.

The company plans to use its proceeds from February 2022 funding to establish a drug development research center (iDear Center), expand the application of the AI platform in new drug development, and expand its business globally.

## Funding rounds

- Series B, Feb 24, 2022, $17M — Korea Development Bank, T.S. Investment, The Wells Investment, Nvestor, Hana Ventures
- Series A, Feb 28, 2021, $5.3M — T.S. Investment, Hana Ventures, Amyloid Solution Inc.
- Seed, Oct 1, 2018 — Medytox Venture Investment

## Investors

- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Seed
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series A, Series B
- Hana Ventures — Series A, Series B
- Amyloid Solution Inc. — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- The Wells Investment (https://capitalatlas.ai/funds/the-wells-investment) — Series B
- Nvestor (https://capitalatlas.ai/funds/nvestor) — Series B